Actively Recruiting
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-04-27
45
Participants Needed
55
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
CONDITIONS
Official Title
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Kidney transplant received 63 6 months
- Active or chronic active AMR according to Banff 2022 classification based on screening kidney biopsy
- Positive C4d on screening biopsy and/or positive HLA Class I or II antigen-specific DSA
- MVI score 63 2 (g 63 1 and ptc 63 1)
- eGFR 63 30 mL/min/1.73 m2
- Vaccinated against meningococcal infection at least 14 days and no more than 3 years prior to Day 1
- Vaccinated for Streptococcus pneumoniae prior to randomization
- Vaccinated for Haemophilus influenzae type B prior to randomization
- Body weight 63 50 kg at screening
You will not qualify if you...
- Biopsy diagnosis at screening of TCMR grade 63 1
- Polyoma virus nephropathy
- Severe thrombotic microangiopathy
- Glomerulonephritis
- ABO-incompatible transplant
- Urine albumin-to-creatinine ratio (uACR) > 2200 mg/g
- Multiorgan or cell transplant recipient (except previous multiple kidney transplants)
- Recent or planned treatments within 90 days for acute rejection or AMR (except stable standard immunosuppressants)
- Known medical or psychological condition, including substance abuse, that may interfere with study or increase risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 55 locations
1
Research Site
Birmingham, Alabama, United States, 35249
Actively Recruiting
2
Research Site
Scottsdale, Arizona, United States, 85259
Actively Recruiting
3
Research Site
Los Angeles, California, United States, 90095
Actively Recruiting
4
Research Site
Orange, California, United States, 92868
Actively Recruiting
5
Research Site
Tampa, Florida, United States, 33606
Actively Recruiting
6
Research Site
Atlanta, Georgia, United States, 30309
Actively Recruiting
7
Research Site
Kansas City, Kansas, United States, 66160
Actively Recruiting
8
Research Site
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
9
Research Site
Detroit, Michigan, United States, 48202
Actively Recruiting
10
Research Site
Livingston, New Jersey, United States, 07039
Actively Recruiting
11
Research Site
New York, New York, United States, 10016
Withdrawn
12
Research Site
New York, New York, United States, 10021
Actively Recruiting
13
Research Site
New York, New York, United States, 10029
Actively Recruiting
14
Research Site
New York, New York, United States, 10032
Actively Recruiting
15
Research Site
Durham, North Carolina, United States, 27705
Actively Recruiting
16
Research Site
Cincinnati, Ohio, United States, 45267
Not Yet Recruiting
17
Research Site
Philadelphia, Pennsylvania, United States, 19140
Not Yet Recruiting
18
Research Site
Charleston, South Carolina, United States, 29425
Withdrawn
19
Research Site
Dallas, Texas, United States, 75235
Actively Recruiting
20
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
21
Research Site
Richmond, Virginia, United States, 23298
Actively Recruiting
22
Research Site
Seattle, Washington, United States, 98195
Actively Recruiting
23
Research Site
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
24
Research Site
Botucatu, Brazil, 18618-687
Actively Recruiting
25
Research Site
Campinas, Brazil, 13083
Actively Recruiting
26
Research Site
Porto Alegre, Brazil, 90020-090
Actively Recruiting
27
Research Site
São Paulo, Brazil, 04038-002
Actively Recruiting
28
Research Site
São Paulo, Brazil, 05403-900
Actively Recruiting
29
Research Site
Calgary, Alberta, Canada, T2N 1N4
Not Yet Recruiting
30
Research Site
Edmonton, Alberta, Canada, T6G 2R7
Actively Recruiting
31
Research Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Actively Recruiting
32
Research Site
London, Ontario, Canada, N6A 5A5
Actively Recruiting
33
Research Site
Toronto, Ontario, Canada, M5G 2N2
Not Yet Recruiting
34
Research Site
Montreal, Quebec, Canada, H4A 3J1
Withdrawn
35
Research Site
Changsha, China, 430033
Actively Recruiting
36
Research Site
Guangzhou, China, 510080
Actively Recruiting
37
Research Site
Nanning, China, 530007
Actively Recruiting
38
Research Site
Shanghai, China, 201114
Actively Recruiting
39
Research Site
Wuhan, China, 430030
Actively Recruiting
40
Research Site
Xi'an, China, 710061
Actively Recruiting
41
Research Site
Seoul, South Korea, 02841
Actively Recruiting
42
Research Site
Seoul, South Korea, 03080
Actively Recruiting
43
Research Site
Seoul, South Korea, 06351
Actively Recruiting
44
Research Site
Seoul, South Korea, 06591
Actively Recruiting
45
Research Site
Seoul, South Korea, 3722
Actively Recruiting
46
Research Site
Barcelona, Spain, 08035
Actively Recruiting
47
Research Site
Barcelona, Spain, 8003
Actively Recruiting
48
Research Site
Zaragoza, Spain, 50009
Actively Recruiting
49
Research Site
Kaohsiung City, Taiwan, 813
Actively Recruiting
50
Research Site
Kaohsiung City, Taiwan, 833401
Actively Recruiting
51
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
52
Research Site
Taoyuan, Taiwan, 333
Withdrawn
53
Research Site
Birmingham, United Kingdom, B15 2GW
Actively Recruiting
54
Research Site
London, United Kingdom, NW3 2QG
Actively Recruiting
55
Research Site
London, United Kingdom, W12 0HS
Actively Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here